Copyright © 2021. Inderes Oyj. All rights reserved.
Etsi
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Cantargia

Analyytikko

Foorumi

Tästä Foorumille

Sisäpiirin kaupat

Nettovaikuttavuus

Artikkeli
Yhtiöjulkaisu
Tiedotteet
Cantargia AB: Nomination Committee appointed ahead of 2023 Annual General Meeting
21.11.
2022

Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2023 Annual General Meeting, and consists of, Jan Särlvik (Fjärde AP-fonden), Mikael Wiberg (Alecta Pensionsförsäkring, Ömsesidigt), Mats Larsson (Första AP-fonden) and Magnus Persson (Chairman of the Board). The Nomination Committee has been appointed in accordance with the guidelines established at the 2022 Annual General Meeting.

Muut analyysit
Cantargia Q3 2022: Focus on Randomised Trials - Redeye
11.11.
2022

Redeye comments on Cantargia's third quarter report and events after the end of the quarter, including the decision to pause three trials.

Tiedotteet
Redeye: Cantargia Q3 2022 - Focus on Randomised Trials
11.11.
2022

Redeye comments on Cantargia's third quarter report and events after the end of the quarter, including the decision to pause three trials.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

Tiedotteet
Cantargia AB: Cantargia publishes interim report for third quarter 2022
10.11.
2022

Cantargia AB's ("Cantargia") interim report for the period January until September 2022 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Tiedotteet
Cantargia AB: Cantargia's CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022
8.11.
2022

Strongly supports therapeutic potential in one of CAN10's lead indications

Muut analyysit
Cantargia: New data support differentiation of nadunolimab - Edison
8.11.
2022

Cantargia has presented new data concerning its IL1RAP-targeting antibody, nadunolimab (CAN04), which demonstrates the drug’s ability to reduce levels of tumour-promoting molecules in a pancreatic cancer (PDAC) microenvironment model.

Tiedotteet
Cantargia AB: Cantargia presents new data at SITC 2022 supporting nadunolimab's promising antitumor clinical efficacy
7.11.
2022

Data shows nadunolimab dual mechanism potently reduces levels of tumor-promoting molecules

Tiedotteet
Cantargia AB: Invitation to presentation of Cantargia's report for the third quarter of 2022 on November 10 at 3.00 p.m. CET
28.10.
2022

Cantargia AB will publish the company's report for the third quarter of 2022 on Thursday, November 10, 2022, at 08:30 a.m. CET.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on November 10, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the third quarter 2022, followed by a Q&A-session.

Muut analyysit
Cantargia: New Preliminary Results and Halt of Recruitment in Three Trials - Redeye
14.10.
2022

Redeye comments on the preliminary results from CAPAFOUR and CESTAFOUR and the decision not to continue recruitment in these trials and CIRIFOUR.

Tiedotteet
Cantargia AB: Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies
14.10.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the clinical trials CAPAFOUR and CESTAFOUR have enrolled enough patients to halt recruitment. Preliminary results show acceptable safety of the chemotherapy combinations with Cantargia's lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), as well as signs of efficacy in a cohort of non-small cell lung cancer (NSCLC) patients treated with nadunolimab and gemcitabine/cisplatin in CESTAFOUR. Consequently, clinical development of nadunolimab will focus on planned randomized trials in the lead indications.

Cantargia